Fiche publication
Date publication
novembre 2022
Journal
Journal of clinical medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr KROEMER Marie
Tous les auteurs :
Zerbit J, Detroit M, Chevret S, Pene F, Luyt CE, Ghosn J, Eyvrard F, Martin-Blondel G, Sarton B, Clere-Jehl R, Moine P, Cransac A, Andreu P, Labruyère M, Albertini L, Huon JF, Roge P, Bernard L, Farines-Raffoul M, Villiet M, Venet A, Dumont LM, Kaiser JD, Chapuis C, Goehringer F, Barbier F, Desjardins S, Benzidi Y, Abbas N, Guerin C, Batista R, Llitjos JF, Kroemer M
Lien Pubmed
Résumé
Given the rapidly evolving pandemic of COVID-19 in 2020, authorities focused on the repurposing of available drugs to develop timely and cost-effective therapeutic strategies. Evidence suggested the potential utility of remdesivir in the framework of an early access program. REMDECO-19 is a multicenter national cohort study assessing the ability of remdesivir to improve the outcome of patients hospitalized with COVID-19.
Mots clés
COVID-19, SARS-CoV-2, pneumonia, remdesivir, survival
Référence
J Clin Med. 2022 11 4;11(21):
